Cephalon Buys Swiss Generics Firm Mepha, Talking Up Diversification
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will buy Mepha for roughly $590 million in cash to double the size of its international business and diversify its business mix.
You may also be interested in...
North American Buyers Turn to European Branded Generics For Growth
Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.
North American Buyers Turn to European Branded Generics For Growth
Europe's tough pricing and reimbursement environment may make it a graveyard for growth in innovative drugs, but there's still plenty of upside in generics, particularly of the branded, specialist kind.
In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.